15 Sep

Poster on second-line MDR-TB medications

We are pleased to share a recent poster presentation: “Administering Second-Line Antituberculous Medications to Children with Multidrug-Resistant Tuberculosis: A Qualitative Study.” The poster was presented by Erica Lessem at the Clinical Pharmacology Workshop on New TB Drugs on September 9, 2013 in Denver Colorado. This poster presents results from a very small qualitative study of clinicians providing care to children with MDR-TB, and points to the need to improved pediatric formulations for second-line drugs.

03 Jul

Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study

Members of the Advocacy Task Force have published a report entitled “Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study.” The paper was published online in the International Journal of Tuberculosis and Lung Disease. The aim of this paper is to present the development of a child-friendly delivery system for second-line medications.

Full reference: Furin J, Brigden G, Lessem E, Becerra MC. Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study. Int J Tuberc Lung Dis. 2013 Sep;17(9):1239-41. doi: 10.5588/ijtld.13.0196. Epub 2013 Jul 3.

07 Jun

Pediatric TB course in Chennai, India

From June 17-19 2013, the National Institute for Research in Tuberculosis and the Sentinel Project on Pediatric Drug-Resistant TB sponsored a training workshop on “Improving the Quality of Care for Children with TB and Drug-Resistant TB” in Chennai, India. The workshop was attended by 48 participants, primarily pediatricians from the public, private, and university sector, including all states of India and Nepal. The course was well-received by participants and all participants were engaged actively in the program. There was lively discussion and debate on both clinical and policy issues. The summary report can be found here, and recommendations can be found here.

11 Apr

Consensus statement on research definitions for drug-resistant tuberculosis in children

We are delighted to announce and share a new resource emerging from our network’s collaboration, “Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children.” The paper was published online in the Journal of Pediatric Infectious Diseases Society yesterday and the full reference is below. It was written by a Sentinel Project Task Force led by James Seddon. The aim of this paper is to advance a consistent terminology for use in research that we hope will result in more comparable data about children with DR-TB which can lead to more efficient syntheses and collective learning.

We also want to thank Professors Anneke Hesseling and Simon Schaaf of Stellenbosch University who provided funds to cover the costs of making this article immediately ‘Open Access.’

Full reference: Seddon JA, Perez-Velez CM, Schaaf HS, Furin JJ, Marais BJ, Tebruegge M, Detjen A, Hesseling AC, Shah S, Adams LV, Starke JR, Swaminathan S, Becerra MC, on behalf of the Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Consensus statement on research definitions for drug-resistant tuberculosis in children. Journal of the Pediatric Infectious Diseases Society, first published online April 10, 2013. doi:10.1093/jpids/pit012

21 Mar

New collection of stories published: “We Can Heal”

We Can Heal ThumbnailOn March 21, 2013, the Sentinel Project on Pediatric Drug-Resistant Tuberculosis and Treatment Action Group (TAG) published We Can Heal, a collection of stories of 30 children in 30 countries affected by this disease. The stories call for urgent attention to this global threat to children, and are a testament to the need for improved programs, policies, and tools. The global community must commit long overdue political will and resources to address the gaps identified in this collection and to tackle all forms of TB in children necessary to achieve zero TB deaths, new infections, and suffering.  

20 Mar

We Can Heal | Prevention, diagnosis, treatment, care and support: Addressing drug-resistant tuberculosis in children

This collection of 30 stories from 30 countries identifies what the TB community needs to achieve zero TB deaths, new infections, and suffering—a target recently called for by more than
500 individuals and organizations. Addressing the gaps in prevention, diagnosis, treatment, care, and support that this report outlines will bring us closer to realizing zero child deaths from
drug-resistant tuberculosis (DR-TB), a preventable and curable disease.

View a PDF version of the document here: “We Can Heal | Prevention, Diagnosis, Treatment, Care and Support: Addressing Drug-Resistant Tuberculosis in Children” (March, 2013)

04 Dec

Request for submissions: Child DR-TB stories

PDF Cover Pic

The stories submission page for Phase II of the Sentinel Project on Pediatric Drug-Resistant Tuberculosis is now live! Check it out here.

As the January 24th deadline approaches, we are still working to collect stories from as many countries as possible to highlight in our next report, which will be launched on World TB Day, March 2013.  Please help us identify stories of children with DR-TB to highlight in our report.  It can be a child who died with or without treatment, or a good outcome — we are gathering both.

Alternatively, if you do not personally know of any cases, but know of a colleague who might, please pass this request along and refer them to the new “submissions page” of the Sentinel Project website.  There are links available on the submissions page where they can download the story collection framework document in English (attached), French, Spanish and Russian — this framework includes a consent form and details the type of information we are looking to include in the stories we collect.

We look forward to working together to advocate for better drugs and drug formulations, diagnostics, and access to care for children with DR-TB!

Stories and/or completed frameworks can be sent to sentinel_project@hms.harvard.edu and questions directed to Lindsay McKenna at Lindsay.McKenna@treatmentactiongroup.org.